title: The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
abstract: OBJECTIVE
  To analyse the relationship between daily calcium intake (DCI) and bone mineral density (BMD) in patients with prostate cancer, and to assess if DCI is a risk factor for osteoporosis in this group of patients.
  
  
  METHODS
  DCI was assessed by a standard questionnaire answered by men with prostate cancer who had had bone densitometry. BMD was measured by dual-energy X-ray absorptiometry in the lumbar spine and different hip sites, in a cross-sectional study including 372 men with prostate cancer free of bone metastases, 71.5% (266) under androgen-deprivation therapy (ADT) and 28.5% (106) after radical prostatectomy (RP). Osteoporosis was defined according to the International Society for Clinical Densitometry official position (2005).
  
  
  RESULTS
  A DCI of <1000 mg, the National Institute of Health recommendation, was detected in 93% of the men, (93.5% under ADT and 91.5% after RP). Osteoporosis was identified in 49.2% (183) of the patients, 54.9% (146) under ADT and 34.9% (37) after RP. The mean DCI was 609.7 mg in men with osteoporosis and 682.8 mg in those without (P < 0.001); in men under ADT the mean DCI remained significantly lower in those with osteoporosis (615.5 vs 700.4 mg, P < 0.001). A multivariate analysis showed that DCI was an independent risk factor for osteoporosis, together with patient age, ADT and its duration.
  
  
  CONCLUSIONS
  DCI seems to be related to BMD; a low DCI was an independent risk factor for osteoporosis in men with prostate cancer. In the study population overall the DCI was inadequate. Urologists should recommend a DCI of >1000 mg in patients with prostate cancer, especially in those under ADT.
authors: Department of Urology. Vall d'Hebron Hospital, Autónoma University School of Medicine, Barcelona, Spain.
authors: Jacques
authors: J
authors: Planas
authors: Juan
authors: J
authors: Morote
authors: Anna
authors: A
authors: Orsola
authors: Carlos
authors: C
authors: Salvador
authors: Enrique
authors: E
authors: Trilla
authors: Lluis
authors: L
authors: Cecchini
authors: Carles X
authors: CX
authors: Raventós
mesh_terms: D015502:Absorptiometry, Photon; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D002136:Calcium, Dietary / Q000008:administration & dosage*; D003430:Cross-Sectional Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010024:Osteoporosis / Q000209:etiology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000150:complications* / Q000628:therapy; D012307:Risk Factors
chemical_list: D000726:Androgen Antagonists; D002136:Calcium, Dietary; D017430:Prostate-Specific Antigen